45 Queen Anne Street, London, W1G 9JF
clinicaltrials@re-cognitionhealth.com
re-cognitionhealth.com
+44(0)20 3355 3536 (tel.)
+44(0)20 3432 7378 (fax)

Short Trial Name:	Clinical trial of MK-1942 for mild to moderate Alzheimer's Disease dementia
Full Trial Name:	A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer's Disease Dementia
Protocol Number:	MK-1942-008
EudraCT Number:	2021-006336-94
IRAS Number:	1006261

SUMMARY PARTICIPANT INFORMATION SHEET

We are inviting you to take part in a research trial

- We would like to invite you to take part in a research trial with a drug, MK-1942.
- This information sheet summarises why the trial is being done and what is involved.
- Taking part in this trial is voluntary. It is up to you to decide whether or not to take part.
- You do not need to take part in this trial to be treated for your Alzheimer's disease dementia.
- You can stop taking part in the trial at any time without giving a reason, by telling your trial doctor your decision.

How to contact us

If you have any questions about this trial, please contact your trial doctor at:

Dr. Emer MacSweeney
Re:Cognition Health
45 Queen Anne Street, London,
W1G 9JF
Tel: 020 3355 3536
clinicaltrials@re-cognitionhealth.com

1 What is the trial?

This trial is testing MK-1942 in people with mild to moderate Alzheimer's disease dementia.

MK-1942 is experimental. It has not been approved for treatment of Alzheimer's disease dementia.

This trial will compare MK-1942 to placebo. A placebo looks like a trial drug, but it has no active ingredients.

This trial is being done to:

- Test the safety of different doses of MK-1942.
- See how well different doses of MK-1942 work, compared to placebo.

If you take part in this trial, you will visit the trial doctor about 9 times. Most visits will last between 1 and 7 hours.

You could be in the trial for about 6 months.

The below diagram shows the trial design:

Trial design:



This trial is being sponsored by the pharmaceutical company Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA ("MSD"). Re-Cognition Health will be paid by MSD.

2 Who can be in this trial?

You can be in this trial if you have mild to moderate Alzheimer's disease dementia.

There may be reasons why you cannot be in this trial. The trial doctor or staff will discuss these reasons with you.

About 408 participants will take part in the trial from approximately 11 countries.

3 What drug will I get?

Sometimes we don't know what the best way is to treat participants. To find out, we need to compare different treatments. We put people into groups and give each group a different treatment. The results are compared to see which one is better. To try to make sure the groups are the same to start with, each participant is put into a group by chance (randomly).

The drug you get will depend on which group you are placed in. This trial has 3 groups:

- **Group 1:** will get a lower dose of MK-1942 (5 mg per dose).
- **Group 2:** will get a higher dose of MK-1942 (8 mg per dose for 1 week and then 15 mg per dose).
- **Group 3:** will get placebo.

A computer will decide which group you are put in. You have an equal chance of being placed into each group. You have a 1 in 2 chance of getting placebo only.

You, your trial doctor, and the trial staff won't know what drug you are getting. In case of a health emergency, they can find out.

MK-1942 and the placebo are capsules. Participants in all groups will take the capsules twice each day (in the morning and evening).

4 Expenses and payments

All trial medication and trial-related tests will be provided at no cost to you. You and your trial partner will be paid stipend payments for your trial site visits and telephone calls. Stipend payments are offered as recompense for your dedicated time,

inconvenience during each visit and for successful completion of questionnaires.

You and your trial partner will get paid between £80 and £160 depending on what is performed at the trial visits. A stipend payment of £20 will be paid per follow-up phone call. The trial doctor or staff will discuss stipend payments with you.

You and your trial partner will be reimbursed for your transportation, hotel, parking, meals, or other reasonable expenses related to your participation in this trial.

If you withdraw from the trial early, you and your trial partner will be reimbursed for the expenses and stipend payments for the portion of the trial that you and your trial partner completed.

5 How will my privacy be protected?

The trial team and Sponsor have strict privacy and confidentiality policies in place to protect your information. The Sponsor will ensure adequate safeguards are in place to protect your data and abide by UK data privacy laws. Information about you will be collected and shared as described in the main participant information sheet, which will be given to you if you would like more information about the trial.

6 What happens next?

If you would like further details on this trial, please contact your trial doctor whose contact details are in the "How to contact us" section at the beginning of this document. If you wish to consider taking part in the trial, you must read and sign the main participant information sheet and consent form.

If you would like to discuss this trial with someone independent (not the trial team), please contact your General Practitioner (GP).

Thank you for reading this information sheet.

Use this space to note down any questions you may want to ask your doctor.